(APOP)
is expected to split Monday, August 15, 2022 with a ratio of 1:5
recently split on Friday, August 12, 2022 with a ratio of 1:3

(APOP), Quotes and News Summary

APOP

Cellect Biotechnology Ltd is a specialty pharmaceutical company for developing therapeutic products for the treatment of rare and orphan diseases. Its lead product, QRX003, is under development for the treatment of Netherton Syndrome, a rare hereditary skin disease. Its pipeline also includes potential treatments for other rare diseases including Peeling skin syndrome, SAM Syndrome, Palmoplantar Keratoderma, and Epidermolysis Bullosa.

Earnings

see more
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-12-20
REV
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-11-09
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target